tetano
Editor, Senior Moderator
Sci Rep
. 2024 Feb 29;14(1):5028.
doi: 10.1038/s41598-024-54920-1. CT-based Assessment at 6-Month Follow-up of COVID-19 Pneumonia patients in China
Xingyu Fang[SUP] #[/SUP][SUP] 1 [/SUP], Yuan Lv[SUP] #[/SUP][SUP] 2 3 [/SUP], Wei Lv[SUP] 1 [/SUP], Lin Liu[SUP] 1 [/SUP], Yun Feng[SUP] 1 [/SUP], Li Liu[SUP] 1 [/SUP], Feng Pan[SUP] 1 [/SUP], Yijun Zhang[SUP] 4 [/SUP]
Affiliations
This study aimed to assess pulmonary changes at 6-month follow-up CT and predictors of pulmonary residual abnormalities and fibrotic-like changes in COVID-19 pneumonia patients in China following relaxation of COVID restrictions in 2022. A total of 271 hospitalized patients with COVID-19 pneumonia admitted between November 29, 2022 and February 10, 2023 were prospectively evaluated at 6 months. CT characteristics and Chest CT scores of pulmonary abnormalities were compared between the initial and the 6-month CT. The association of demographic and clinical factors with CT residual abnormalities or fibrotic-like changes were assessed using logistic regression. Follow-up CT scans were obtained at a median of 177 days (IQR, 170-185 days) after hospital admission. Pulmonary residual abnormalities and fibrotic-like changes were found in 98 (36.2%) and 39 (14.4%) participants. In multivariable analysis of pulmonary residual abnormalities and fibrotic-like changes, the top three predictive factors were invasive ventilation (OR 13.6; 95% CI 1.9, 45; P < .001), age > 60 years (OR 9.1; 95% CI 2.3, 39; P = .01), paxlovid (OR 0.11; 95% CI 0.04, 0.48; P = .01) and invasive ventilation (OR 10.3; 95% CI 2.9, 33; P = .002), paxlovid (OR 0.1; 95% CI 0.03, 0.48; P = .01), smoker (OR 9.9; 95% CI 2.4, 31; P = .01), respectively. The 6-month follow-up CT of recent COVID-19 pneumonia cases in China showed a considerable proportion of the patients with pulmonary residual abnormalities and fibrotic-like changes. Antivirals against SARS-CoV-2 like paxlovid may be beneficial for long-term regression of COVID-19 pneumonia.
Keywords: COVID-19; Follow-up; Pneumonia; SARS-CoV-2; Tomography, X-ray.
. 2024 Feb 29;14(1):5028.
doi: 10.1038/s41598-024-54920-1. CT-based Assessment at 6-Month Follow-up of COVID-19 Pneumonia patients in China
Xingyu Fang[SUP] #[/SUP][SUP] 1 [/SUP], Yuan Lv[SUP] #[/SUP][SUP] 2 3 [/SUP], Wei Lv[SUP] 1 [/SUP], Lin Liu[SUP] 1 [/SUP], Yun Feng[SUP] 1 [/SUP], Li Liu[SUP] 1 [/SUP], Feng Pan[SUP] 1 [/SUP], Yijun Zhang[SUP] 4 [/SUP]
Affiliations
- PMID: 38424447
- PMCID: PMC10904828
- DOI: 10.1038/s41598-024-54920-1
This study aimed to assess pulmonary changes at 6-month follow-up CT and predictors of pulmonary residual abnormalities and fibrotic-like changes in COVID-19 pneumonia patients in China following relaxation of COVID restrictions in 2022. A total of 271 hospitalized patients with COVID-19 pneumonia admitted between November 29, 2022 and February 10, 2023 were prospectively evaluated at 6 months. CT characteristics and Chest CT scores of pulmonary abnormalities were compared between the initial and the 6-month CT. The association of demographic and clinical factors with CT residual abnormalities or fibrotic-like changes were assessed using logistic regression. Follow-up CT scans were obtained at a median of 177 days (IQR, 170-185 days) after hospital admission. Pulmonary residual abnormalities and fibrotic-like changes were found in 98 (36.2%) and 39 (14.4%) participants. In multivariable analysis of pulmonary residual abnormalities and fibrotic-like changes, the top three predictive factors were invasive ventilation (OR 13.6; 95% CI 1.9, 45; P < .001), age > 60 years (OR 9.1; 95% CI 2.3, 39; P = .01), paxlovid (OR 0.11; 95% CI 0.04, 0.48; P = .01) and invasive ventilation (OR 10.3; 95% CI 2.9, 33; P = .002), paxlovid (OR 0.1; 95% CI 0.03, 0.48; P = .01), smoker (OR 9.9; 95% CI 2.4, 31; P = .01), respectively. The 6-month follow-up CT of recent COVID-19 pneumonia cases in China showed a considerable proportion of the patients with pulmonary residual abnormalities and fibrotic-like changes. Antivirals against SARS-CoV-2 like paxlovid may be beneficial for long-term regression of COVID-19 pneumonia.
Keywords: COVID-19; Follow-up; Pneumonia; SARS-CoV-2; Tomography, X-ray.